STU:640 (Hong Kong)
Â
Registered Shs Unitary 144A/Reg S
€
0.49
+0.014 (+2.97%)
Jul 3
Business Description
China Resources Pharmaceutical Group Ltd
ISIN : HK0000311099
Share Class Description:
STU:640: Registered Shs Unitary 144A/Reg STotal Employee Number:
85,600Compare
Compare
Traded in other countries / regions
03320.Hong Kong640.GermanyCRPGF.USA IPO Date
2016-10-31Description
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.39 | |||||
Equity-to-Asset | 0.18 | |||||
Debt-to-Equity | 1.41 | |||||
Debt-to-EBITDA | 4.07 | |||||
Interest Coverage | 6.93 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 1.61 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.9 | |||||
3-Year EBITDA Growth Rate | 9.8 | |||||
3-Year EPS without NRI Growth Rate | 5.4 | |||||
3-Year FCF Growth Rate | 27.5 | |||||
3-Year Book Growth Rate | 5.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.47 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.46 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.06 | |||||
9-Day RSI | 49.82 | |||||
14-Day RSI | 45.38 | |||||
3-1 Month Momentum % | -23.13 | |||||
6-1 Month Momentum % | 8.19 | |||||
12-1 Month Momentum % | -7.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.42 | |||||
Quick Ratio | 1.11 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 65.52 | |||||
Days Sales Outstanding | 141.56 | |||||
Days Payable | 98.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 5.14 | |||||
Dividend Payout Ratio | 0.17 | |||||
3-Year Dividend Growth Rate | -1.2 | |||||
Forward Dividend Yield % | 5.14 | |||||
5-Year Yield-on-Cost % | 7.91 | |||||
Shareholder Yield % | -34.45 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 16.51 | |||||
Operating Margin % | 5.21 | |||||
Net Margin % | 1.5 | |||||
EBITDA Margin % | 6.64 | |||||
FCF Margin % | 6.29 | |||||
OCF Margin % | 7.61 | |||||
ROE % | 8.18 | |||||
ROA % | 1.47 | |||||
ROIC % | 6.82 | |||||
3-Year ROIIC % | 2.28 | |||||
ROC (Joel Greenblatt) % | 13.62 | |||||
ROCE % | 10.16 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 6.23 | |||||
Forward PE Ratio | 6.14 | |||||
PE Ratio without NRI | 5.37 | |||||
Shiller PE Ratio | 6.72 | |||||
Price-to-Owner-Earnings | 2.17 | |||||
PEG Ratio | 0.59 | |||||
PS Ratio | 0.09 | |||||
PB Ratio | 0.48 | |||||
Price-to-Tangible-Book | 1.62 | |||||
Price-to-Free-Cash-Flow | 1.47 | |||||
Price-to-Operating-Cash-Flow | 1.23 | |||||
EV-to-EBIT | 10.03 | |||||
EV-to-Forward-EBIT | 9.64 | |||||
EV-to-EBITDA | 7.75 | |||||
EV-to-Forward-EBITDA | 8.09 | |||||
EV-to-Revenue | 0.51 | |||||
EV-to-Forward-Revenue | 0.53 | |||||
EV-to-FCF | 8.09 | |||||
Price-to-GF-Value | 0.76 | |||||
Price-to-Projected-FCF | 0.16 | |||||
Price-to-DCF (Earnings Based) | 0.39 | |||||
Price-to-DCF (FCF Based) | 0.05 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.6 | |||||
Price-to-Graham-Number | 0.62 | |||||
Earnings Yield (Greenblatt) % | 9.97 | |||||
FCF Yield % | 66.33 | |||||
Forward Rate of Return (Yacktman) % | 53.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
China Resources Pharmaceutical Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 32,619.577 | ||
| EPS (TTM) (€) | 0.078 | ||
| Beta | -0.8729 | ||
| 3-Year Sharpe Ratio | -0.52 | ||
| 3-Year Sortino Ratio | -0.77 | ||
| Volatility % | 39.43 | ||
| 14-Day RSI | 45.38 | ||
| 14-Day ATR (€) | 0.016069 | ||
| 20-Day SMA (€) | 0.49315 | ||
| 12-1 Month Momentum % | -7.21 | ||
| 52-Week Range (€) | 0.458 - 0.695 | ||
| Shares Outstanding (Mil) | 6,282.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
China Resources Pharmaceutical Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
China Resources Pharmaceutical Group Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-26 | In 53 days | ||
| HKD 0.139000 Cash Dividend | 2026-06-17 | 0.51 (+0.00%) | ||
| General meeting for 2025 | 2026-06-12 15:30 | 0.52 (-0.96%) | ||
| Annual report for 2025 | 2026-04-28 | 0.56 (-0.88%) | ||
| HKD 0.078900 Cash Dividend | 2025-09-11 | 0.53 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-26 | 0.59 (+5.41%) | ||
| HKD 0.056000 Cash Dividend | 2025-05-28 | 0.56 (+0.00%) | ||
| General meeting for 2024 | 2025-05-23 15:30 | 0.56 (+0.90%) | ||
| Annual report for 2024 | 2025-04-27 | 0.55 (+0.00%) | ||
| HKD 0.090800 Cash Dividend | 2024-09-10 | 0.59 (+2.61%) |
Show
Entries
China Resources Pharmaceutical Group Ltd Frequently Asked Questions
What is China Resources Pharmaceutical Group Ltd(STU:640)'s stock price today?
The current price of STU:640 is €0.49. The 52 week high of STU:640 is €0.70 and 52 week low is €0.46.
When is next earnings date of China Resources Pharmaceutical Group Ltd(STU:640)?
The next earnings date of China Resources Pharmaceutical Group Ltd(STU:640) is 2026-08-26 Est..
Does China Resources Pharmaceutical Group Ltd(STU:640) pay dividends? If so, how much?
The Dividend Yield %  of China Resources Pharmaceutical Group Ltd(STU:640) is 5.14% (As of Today), Highest Dividend Payout Ratio of China Resources Pharmaceutical Group Ltd(STU:640) was 0.36. The lowest was 0.17. And the median was 0.19. The  Forward Dividend Yield % of China Resources Pharmaceutical Group Ltd(STU:640) is 5.14%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on China Resources Pharmaceutical Group Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers